Tropical spastic paraparesis overview

Tropical spastic paraparesis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tropical spastic paraparesis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tropical spastic paraparesis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tropical spastic paraparesis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tropical spastic paraparesis overview

CDC on Tropical spastic paraparesis overview

Tropical spastic paraparesis overview in the news

Blogs on Tropical spastic paraparesis overview

Directions to Hospitals Treating Tropical spastic paraparesis

Risk calculators and risk factors for Tropical spastic paraparesis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

## Overview

[edit | edit source]

Tropical spastic paraparesis is an infection of the spinal cord by Human T-lymphotropic virus resulting in paraparesis or weakness of the legs. As the name suggests, it is most common in tropical regions, including the Caribbean and Africa.

## Treatment

[edit | edit source]

### Medical Therapy

[edit | edit source]

There is no established treatment program for HAM/TSP although some patients may be given steroids. Clinical studies using interferon alpha and plasmapheresis have not shown significant patient improvement. Spasticity may be treated with lioresal or tizanidine. Urinary dysfunction should be treated with self-catheterization or oxybutynin.

### Primary Prevention

[edit | edit source]

Blood transfusion products are screened for HTLV-1 antibodies.

## References

[edit | edit source]

Template:WH Template:WS